Aging in Place Technology Watch

DECEMBER 17, 2019

Data-driven diabetes care: Smartphone synching of readings with clinical content and support systems – can used as research tools and ways to improve care ( Novo Nordisk , IBM Watson/Medtronic , Glooko ). category tags: mHealth-Digital Health-Telehealth-Voice Health. category tags: mHealth-Digital Health-Telehealth-Voice Health.

mHealth 96

mHealth Digital Health Telehealth 96

Insulin Nation

SEPTEMBER 29, 2017

In 2016, when Medtronic released its 670G pump, which could automate basal insulin delivery but not bolus, some wondered why the pump wasn’t more fully automated. The pharma analysis firm Bernstein predicts that Fiasp will bring over $500 million in sales to Novo Nordisk by 2020, according to a FiercePharma report.

62

62

Lloyd Price

FEBRUARY 22, 2024

Technology: Closed-loop neuromodulation - Implantable devices like Medtronic's Intellis and Abbott's BurstDRT continuously analyse pain signals and adjust stimulation automatically for personalised pain relief.

Pain management 56

Pain management Mental health Telehealth healthcare technology 56

Insulin Nation

JUNE 13, 2017

In the same presentation, another researcher described how the price of insulin has skyrocketed in recent years and that incremental improvements in insulin don’t justify their increased price tag. Medtronic officially launched its 670G for commercial sale in the U.S. Miguel Perales M.D. DrMiguelPerales) June 10, 2017.

Pharmaceuticals 61

Pharmaceuticals 61

Lloyd Price

AUGUST 5, 2023

The company is led by former Medtronic CEO Omar Ishrak. Additionally, the company has been criticized for its high price tag. The deal valued Allurion at $500 million. Compute Health is a blank-check company that was formed to acquire a health care technology business. The SPAC merger was announced in February 2023.

Medical Technology 52

Medical Technology healthcare technology 52

Lloyd Price

JULY 30, 2018

In January, a single therapy to treat a rare form of blindness received a price tag of $850,000. In his view, venture capital often lean towards the therapeutics companies that fit into the low social complexity/high medical complexity quadrant, such as costly novel drugs for cancer or diabetes. Who's left out?

Pharmaceuticals 84

Pharmaceuticals Primary Care 84